James Nam, PharmD

Adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone leads to deeper remissions in transplant-eligible, newly diagnosed multiple myeloma, data suggest.

Adding talazoparib to atezolizumab maintenance can improve progression-free survival in patients with SLFN11+ extensive-stage small cell lung cancer, a phase 2 trial suggests.

Zanidatamab can produce rapid and durable responses in patients with advanced HER2-positive biliary tract cancer, phase 2 data suggest.

The use of anti-inflammatory analgesics, such as aspirin, may extend survival for patients with ovarian cancer.

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Using the Questions on Life Satisfaction (FLZ-M) questionnaire, researchers determined the extent of life satisfaction across 10 subdomains reported by adolescents and young adults with cancer.

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.